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MINING MEDICAL DATA IN A CLINICAL ENVIRONMENT
Tim V. Ivanovskiy
ABSTRACT
The availability of new treatments for a disease depends on the success of clinical trials. In
order for a clinical trial to be successful and approved, medical researchers must first recruit
patients with a specific set of conditions in order to test the effectiveness of the proposed
treatment. In the past, the accrual process was tedious and time-consuming. Since accruals
rely heavily on the ability of physicians and their staff to be familiar with the protocol eligibility
criteria, candidates tend to be missed. This can result and has resulted in unsuccessful trials.
A recent project at the University of South Florida aimed to assist research physicians at
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, with a screening process
by utilizing a web-based expert system, Moffitt Expedited Accrual Network System (MEANS).
This system allows physicians to determine the eligibility of a patient for several clinical trials
simultaneously.
We have implemented this web-based expert system at the H. Lee Moffitt Cancer Center
& Research Institute Gastroenterology (GI) Clinic. Based on our findings and staff feedback,
the system has undergone many optimizations. We used data mining techniques to analyze
the medical data of current gastrointestinal patients. The use of the Apriori algorithm allowed
us to discover new rules (implications) in the patient data. All of the discovered implications
were checked for medical validity by a physician, and those that were determined to be valid
were entered into the expert system. Additional analysis of the data allowed us to streamline
the system and decrease the number of mouse clicks required for screening. We also used a
probability-based method to reorder the questions, which decreased the amount of data entry
required to determine a patient’s ineligibility.
vi
CHAPTER 1
INTRODUCTION
1.1 Overview
The application of Artificial Intelligence to real-world issues has produced promising re-
sults. The work presented in this thesis is aimed toward improving the existing medical
expert system MEANS–which stands for Moffitt Expedited Accrual Network System–to be
more physician-friendly. This expert system is designed to be used as a tool for helping physi-
cians screen patients for eligibility for clinical trials. It is our goal to see that the system
eventually becomes part of the standard of care at Moffitt Cancer Center, Tampa, Florida,
and its affiliates. Various techniques were used to increase user friendliness and acceptability
of the expert system, including changes to the interface and system flow. In addition, data
mining and statistical analysis techniques were used in order to decrease the amount of data
entry needed from the user.
I will begin with a brief introduction to previous work on medical expert systems in
Section 2.1 and continue with an explanation of our medical expert system in Section 2.2.
Chapter 3 will take us into current work and the changes that were made to the expert
system, including work that was done to increase the system’s user friendliness and minimize
the amount of time required to determine a patient’s eligibility for clinical trials. I will
conclude with results and future challenges in Chapter 4.
1.2 Statistics
In the United States, cancer is among leading causes of death. The American Cancer
Society estimated that the number of new cancer cases in 2005 was 1,372,910 where 570,280
resulted in death. The National Institute of Health estimates that the cost of cancer in the
United States was around $189.8 billion in 2004, from which only $64.4 billion was for direct
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medical costs. The remaining, $125.4 billion was the cost of lost productivity due to illness
or premature death. [4]
1.3 Clinical Trials
Also called clinical studies, clinical trials are defined by National Cancer Institute as: “A
type of research study that tests how well new medical approaches work in people. These
studies test new methods of screening, prevention, diagnosis, or treatment of a disease” [16].
Clinical trials can also be defined as a way to “evaluate the effectiveness and safety of medi-
cations or medical devices by monitoring their effects on large groups of people” [20]. Clinical
trials can also be referred as clinical study.
2
CHAPTER 2
PREVIOUS WORK
2.1 Similar Systems
The use of artificial intelligence in medicine is not a new concept. Researchers realized in as
early as 1950’s that computers could be used to aid physicians with clinical decision making.
Since then, physicians and computer scientists started analyzing medical information in a
way that could be used by automated decision aids with the help of artificial intelligence for
a certain domain. The term “knowledge engineering” refers to the use of computer-based
symbolic reasoning, including knowledge representation, acquisition, explanation, and self
modification that comes from self awareness [26]. In Section 2.2, I will show that our system
is capable of self modification based on Bayes’ learning algorithm.
One of the earliest expert systems, called DENDRAL was developed in early 1965 at Stan-
ford University. Edward Feigenbaum, Joshua Lederberg and Bruce Buchanan were interested
in the exploration of the mechanization of scientific reasoning and the formalization of sci-
entific knowledge. Mass spectrometry was emerging as a technology of choice for chemical
analysis. Therefore, they decided to apply their idea to the issue of how to properly rep-
resent then-existing chemical graph structures and then generate all possible structures in
the mass spectral analysis domain [19, 28]. DENDRAL was based on a set of rule-based if-
then reasoning to deduce the molecular structure of organic chemical compounds from known
mass spectrometry data and chemical analyses. The project also created the standards for
expert systems by separating internal operations of the system from the explicit rules of the
knowledge [28].
The DENDRAL project gave rise to a famous antimicrobial therapy consultation system
called MYCIN [25, 27, 28]. Shortliffe et al. set out to create a system that will be compatible
with the physician’s own decision-making process, and MYCIN was the result of their efforts.
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It was designed to be used as a tool to assist physicians with the selection of antibiotic
treatments for patients with bacterial infections. It was actually the first expert system to
incorporate in its design a separate and modifiable knowledge base that consisted of if-then
or “PREMISE” and an “ACTION” rules as described by Shortliffe et al. [25].
The success of DENDRAL and MYCIN not only signifies major achievements in artificial
intelligence, but it also helped touch off the development of expert systems. EMYCIN, which
actually moved into the commercial software market, was developed from MYCIN. EMYCIN
was a generic, domain-independent expert system shell that could be used to build a rule-
based expert system in any domain [28]. Janice S. Aikins et al. used the EMYCIN framework
to build a medical expert system for the interpretation of pulmonary function tests for the
patients with the lung disease called PUFF [3]. Another spin-off from MYCIN was a teaching
expert system called NEOMYCIN. It was a combination of the knowledge base of MYCIN
and a teaching program called GUIDON [7].
2.2 About the MEANS System
The medical expert system MEANS – Moffitt Expedited Accrual Network System – was
originally developed at the University of South Florida around 1998 by Fletcher et al. [5]. The
purpose of the system was to automate the selection of patients for cancer clinical trials. Since
its conception, MEANS has been improved dramatically with addition of various optimization
techniques. The original version, developed by Fletcher et al., was a qualitative rule-based
system. Cost-effectiveness of the selection process was addressed by Kokku et al. In their work,
Kokku et al. looked at the cost-optimization problem of ordering related tests and minimizing
the pain factor associated with the number of tests needed for answering eligibility criteria
questions [18]. Physicians could reduce the overall cost of the screening process by ordering less
expensive tests earlier in the process and then use those results to rule out a patient [9]. Savvas
Nikiforou created a Knowledge Entry system in 2002 [21]. Until then, protocol expressions
had to be coded by a programmer and took a significant amount of time and effort.
Goswami et al. experimented with Bayes’ probabilistic reordering agent on retrospective
data. Their experiments showed that the application of Bayes’ probabilistic reordering agent
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could reduce data entry by more than 20% [9, 13]. Probability-based reordering was added to
the expert system by Goswami et al.; however, until now probabilistic knowledge gathering
was not properly implemented in MEANS due to conceptual differences of the test system
that Goswami et al. used to test the probability-based reordering agent. In Section 3.2.3 I
will explain the additional modifications which that done to MEANS.
2.3 MEANS Architecture
The MEANS is divided into two main parts: Patient Assignment and Knowledge Entry.
The development of the Patient Assignment subsystem was started by Fletcher et al. [5].
Kokku et al. continued development of the subsystem and implemented heuristics for ordering
medical tests to minimize overall cost [18]. Goswami et al. added a probabilistic agent to
the system [13]. The Knowledge Entry subsystem was developed by Nikiforou. It has a
friendly web-based user interface which allows encoding of clinical protocols for use by the
Patient Assignment system [21]. To fully complete the system, I refined the implementation
of the probabilistic agent, streamlined the system flow and added a reporting subsystem. The
detailed system architecture is shown in Figure 2.1.
As seen in Figure 2.1, the knowledge base contains information about clinical trials – stored
as general and domain knowledge – together with implications and probabilistic knowledge.
The probabilistic knowledge is gathered by the system every time an answer is evaluated by
MEANS. Once a sufficient number of patients have been screened, the probabilistic knowledge
can be used to reorder the questions. The database contains the information on all previously
screened patients which includes the trials for which patients were screened as well as their
current eligibility for screened trials and any previously provided answers. At any time, the
user has the ability to change or delete an answer via the web-based user interface.
2.4 Knowledge Entry
The medical knowledge acquisition for MEANS is done via the Knowledge Entry subsys-
tem, as seen in Figure 2.1. A protocol must be encoded using only the types of questions,
listed in Table 2.1. For a numeric question, a range of numeric values is provided as an answer;
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Figure 2.1 Expert System Architecture
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for a yes/no question, yes or no may be selected as an eligible answer; for a multiple-choice
question, all possible values are provided. The Knowledge Entry subsystem permits the use
of logical expressions – such as AND and OR – to create combined questions. Once a protocol
is encoded, the Knowledge Entry subsystem generates two expressions per question: 1) the
Acceptance Expression, and 2) the Rejection Expression.
2.4.1 Question Types
All of the protocols are encoded utilizing three types of questions: 1) Numeric, 2) Yes/No,
and 3) Multiple-choice. A sample of how each question appears in MEANS is shown in
Table 2.1.
Table 2.1 Types of Questions
Question Type Example Acceptable Answer
Numeric
Numeric Value
Normal (Auto Fill)
Defer For Later
Yes/No
Yes
No
Defer For Later
Multiple Choice
Any Value
From
Dropdown
2.4.2 Protocol Example
This section shows how a simplified protocol can be encoded for use in MEANS. First, the
protocol eligibility (inclusion/exclusion) criteria is interpreted. A sample protocol is shown in
Table 2.2. Then, the protocol is broken down into separate questions, and the questions that
the appropriate answers are entered into the Knowledge Entry system are shown in Table 2.3.
Lastly, the Knowledge Entry subsystem converts the protocol into two types of expressions: 1)
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the Acceptance Expression and 2) the Rejection Expression. Both expressions for our sample
protocol are listed in the Table 2.4. I will discuss the need for both expressions in Section 2.5.
Table 2.2 Sample Protocol: Criteria
Inclusion Criteria
1. Patient must be male between the ages of 40 and 55
2. Have life expectancy of greater than 12 weeks
3. Able and willing to give written consent
4. Have pathological diagnosis of adenocarcinoma of the stomach
Exclusion Criteria
1. Current tobacco user
2. Participation in other clinical trials
Table 2.3 Sample Protocol: Encoding
# Question Eligibility Answer
1.
Age ≥ 40 and ≤ 55
−−−−− AND −−−−−
Sex Male
2. Life expectancy of > 12 weeks? Yes
3. Able and willing to give written consent? Yes
4. Pathological diagnosis of adenocarcinoma of the stomach? Yes
5. Current tobacco user? No
6. Patient on any other trial? No
Table 2.4 Sample Protocol: Acceptance and Rejection Expressions
Acceptance Expression
{(Age: ≥ 40) and (Age: ≤ 55) and (Sex = Male)} AND
(Life expectancy of > 12 weeks = Yes) AND
(Able and willing to give written consent = Yes) AND
(Pathological diagnosis of adenocarcinoma of the stomach = Yes) AND
(Current tobacco user = No) AND
(On any other trial = No) AND
Rejection Expression
{(Age: < 40) or (Age: > 55) or (Sex = Female)} OR
(Life expectancy of > 12 weeks = No) OR
(Able and willing to give written consent = No) OR
(Pathological diagnosis of adenocarcinoma of the stomach = No) OR
(Current tobacco user = Yes) OR
(On any other trial = Yes) OR
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2.5 MEANS Eligibility Algorithm
As discussed in Section 2.4, the Knowledge Entry subsystem is used to encode a protocol’s
eligibility criteria into the form that will be interpreted by MEANS. At any given time, a
patient’s status for a protocol, which is determined by the assignment agent (Figure 2.1), is in
one of three states: 1) Eligible, 2) Ineligible, or 3) More Information Needed. If the acceptance
criteria can be evaluated and is TRUE, then the patient is Eligible for the protocol. If the
rejection criteria can be evaluated and is TRUE, then the patient status is set to Ineligible.
If neither the acceptance nor rejection criteria can be evaluated, then the patient’s status is
set to More Information Needed. The reason for the determination of each state is listed in
Table 2.5. The MEANS eligibility algorithm is shown in Figure 2.2. The eligibility algorithm
is run for each protocol. Also, I should mention that the user is only presented with 10
questions at a time (line 15). Each time a user provides the system with new answers, the
eligibility criteria is evaluated (line 18).
The discovery of new implications will allow questions that have not been asked to be
answered by the system, thus decreasing the amount of data entry (Figure 2.2, line 17).
Table 2.5 Patient’s State(s) During Screening
State Reason
Eligible Acceptance Criteria = TRUE
Ineligible Rejection Criteria = TRUE
More Information Needed Acceptance or Rejection can’t be determined
2.6 Data Mining
Data mining techniques allow researchers to search through enormous amounts of data in
order to discover association rules, emerging patterns and dependency rules. Data mining has
been successfully applied to a number of application domains, including telecommunications,
commerce, astronomy, geological survey, security, census analysis and text analysis [24, 30].
The identification of sets of items, products, symptoms and characteristics that often occur
together in a given database are often seen as basic tasks of data mining.
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1: for (each protocol)
2: {
3: if (New Patient)
4: {
5: Protocol Status = ”More Info Needed”;
6: }
7: while (Protocol Status == ”More Info Needed”) do
8: {
9: Read Unanswered Questions;
10: if (Unanswered Questions List == 0)
11: {
12: Read Deferred Questions;
13: }
14: Sort Questions By Importance;
15: Ask Questions From User;
16: Read NEW Answers;
17: Apply Implications;
18: Evaluate Acceptance Criteria;
19: if (Acceptance Criteria == TRUE)
20: {
21: Generate Reason For Eligibility;
22: Protocol Status = ELIGIBLE;
23: }
24: else
25: {
26: Evaluate Rejection Criteria;
27: if (Rejection Criteria == TRUE)
28: {
29: Generate Reason For Ineligibility;
30: Protocol Status = INELIGIBLE;
31: }
32: }
33: if (Acceptance Criteria 6= TRUE and Rejection Criteria 6= TRUE)
34: {
35: Protocol Status = More Info Needed;
36: }
37: }
38: }
Figure 2.2 MEANS Eligibility Algorithm
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2.6.1 Association Rules
The problem of association rule mining together with an algorithm for its solution was
originally introduced by Agrawal et al. in 1993 [1]. It was designed for per-transaction base
analysis of a supermarket database. The goal was to identify associations between sets of items
with some minimal confidence. Agrawal et al. proposed a faster algorithm called Apriori to
solve the association rule problem in 1994. [2]
The problem can be described as follows: Let I = {ı1, ı2 , . . . ,ım} be a set of all items.
Let D be a database of transactions, where each transaction T consists of a set of items such
that T ⊆ I. A transaction T contains X, a set of items in I, if X ⊆ T. An association rule
XY is written in the form of an implication as X ⇒ Y, where X ⊂ I, Y ⊂ I and X ∩ Y =
0. An association rule must have a confidence and a support. The confidence c for the rule X
⇒ Y holds if c% of transactions in D that contain X also contain Y. The rule X ⇒ Y has a
minimum support s in the transaction set D if s% of transactions in D contain X ∪ Y . [1, 2]
The original motivation for the Apriori algorithm came from the need to analyze super-
market analysis data so that customer behavior could be examined in terms of purchased
products. How often the products are purchased together are described by a frequent set. An
example of this association rule is: 90% of transactions that had butter and eggs also contained
milk. In this example, the confidence c is 0.9 (90%).
Association rules are discovered by looking at item sets that have specified minimum
support s (coverage). An item is a combination of attribute-value pairs. First we generate
one-item sets for all attributes that have minimum support greater than a given minimum
support value. The next step of the algorithm is the generation of two-item sets (two attribute-
value pairs). We must note that we only generate new item sets if their minimum support
is greater than a given minimum support value. Item sets in which an attribute takes two
separate values will not be generated because it is impossible. For example, it is impossible
for the temperature to be hot and cold at the same time; therefore, such an item-set will not
be generated. The algorithm will generate new item sets until no more sets can be generated
with given minimum support.
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Here is an example of how the algorithm works: Suppose we have database I that consists
of five (5) patients (Table 2.6). From this table, we can see that our database consist of 7
attributes and 17 values. Using a minimum support (s) of 3, we can find all possible association
rules. I will discuss the confidence (c) level after we find the rules from our database I.
Table 2.6 Apriori Example: Database
Sample Patients
Attributes Goal
# Metastatic Biopsy Complaint Severity Race Age Treatment
1 No Yes Some High French 10 to 20 Yes
2 Yes No Some Low Russian 10 to 20 Yes
3 No Yes None Low German 40 to 70 No
4 No Yes Some Low German 20 to 40 Yes
5 No No None High French > 70 No
First we must create one-item sets from our database. We will scan our database and
locate all possible attribute-value pairs that have occurred. We can see that our database I
contains 17 one-item sets (Table 2.7).
After all one-item sets are found, they are thresholded by a given minimum support. If
the support (frequency) of an item set is below a given minimum support, then the item set
is excluded from further investigation. From Table 2.7 we can see that only 5 one-item sets
have their support above or equal to the given minimum support of 3. For the next step we
will only use the item sets that have passed the minimum support test.
In this step we will use one-item sets to compose two-item sets. The resulting two-item
sets are shown in Table 2.8. We ended up with 10 two-item sets; however, only 2 out of the
10 pass the minimum support check. Only the first two two-item sets will be used in the next
step of generating three-item sets.
Table 2.9 contains the resulting three-item sets. Since our minimum support was set at 3,
none of the newly-generated three-item sets pass the minimum support check; hence, we will
stop the generation of item sets at this time and will return to our two-item sets.
By looking at the two-item sets (Table 2.8) we will generate association rules. When
Metastatic is No and Biopsy is Yes, this combination occurs 3 out of 4 times; however, the
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Table 2.7 Apriori Example: One-item Sets
One-item Sets
# Attribute Value Support Min Sup Check
1 Metastatic No 4 X
2 Biopsy Yes 3 X
3 Complaint Some 3 X
4 Severity Low 3 X
5 Treatment Yes 3 X
6 Biopsy No 2 ×
7 Complaint None 2 ×
8 Severity High 2 ×
9 Race French 2 ×
10 Race German 2 ×
11 Age 10 to 20 2 ×
12 Treatment No 2 ×
13 Metastatic Yes 1 ×
14 Race Russian 1 ×
15 Age 40 to 70 1 ×
16 Age 20 to 40 1 ×
17 Age > 70 1 ×
Table 2.8 Apriori Example: Two-item Sets
Two-item Sets
# Attribute/Value Support Min Sup Check
1 Metastatic=No Biopsy=Yes 3 X
2 Complaint=Some Treatment=Yes 3 X
3 Metastatic=No Complaint=Some 2 ×
4 Metastatic=No Severity=Low 2 ×
5 Metastatic=No Treatment=Yes 2 ×
6 Biopsy=Yes Complaint=Some 2 ×
7 Biopsy=Yes Severity=Low 2 ×
8 Biopsy=Yes Treatment=Yes 2 ×
9 Complaint=Some Severity=Low 2 ×
10 Severity=Low Treatment=Yes 2 ×
13
Table 2.9 Apriori Example: Three-item Sets
Three-item Sets
# Attribute/Value Support Min Sup Check
1 Metastatic=No Biopsy=Yes Complaint=Some 2 ×
2 Metastatic=No Biopsy=Yes Treatment=Yes 2 ×
3 Complaint=Some Treatment=Yes Metastatic=No 2 ×
4 Complaint=Some Treatment=Yes Biopsy=Yes 2 ×
combination when Biopsy is Yes and Metastatic is No occurs 3 out of 3 times. These two
rules are interpreted as follows: IF Metastatic=No THEN Biopsy=Yes; IF Biopsy=Yes THEN
Metastatic=No.
From our sample database (Table 2.6) we were able to discover 4 rules with a minimum
support of 3. I listed all of the discovered rules in Table 2.10. I should also point out that
the table contains a confidence column. According to the table we can see that rule #1 has
occurred 3 out of 4 times in our database. This gives the rule a confidence level of 75%
(c=0.75). The other 3 rules have a confidence level of 1 (c=100%).
Table 2.10 Apriori Example: Rules
Sample Rules
# Rules Support Confidence
1 Metastatic=No ⇒ Biopsy=Yes 3 out of 4 75.00%
2 Biopsy=Yes ⇒ Metastatic=No 3 out of 3 100.00%
3 Complaint=Some ⇒ Treatment=Yes 3 out of 3 100.00%
4 Treatment=Yes ⇒ Complaint=Some 3 out of 3 100.00%
Since we will be mining medical data, we must use a confidence level of 1 (c=1). Based
on that, we would only be interested in rules 2, 3, and 4. To complete our process of medical
data mining, rules 2, 3, and 4 will need to be validated by a physician before we can declare
them to be valid rules.
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2.6.2 Mining Medical Data
As seen in Figure 2.1, implications are part of the knowledge base. In Section 3.2.2 I will
explore implications in greater detail, but for now a brief overview will be sufficient in order
to convey our purpose. To decrease the amount of data entry needed to determine a patient’s
eligibility, we explored the use of data mining.
Detection of trends and anomalies in populations has produced significant advances. In
August of 1854 Dr. John Snow used statistical observations to find the source of Cholera
transmission, thus stopping the Cholera outbreak in Britain. Edward Jenner used the ob-
servation that milkmaids who suffered from the mild disease of cowpox never contracted the
more serious smallpox. After he conducted his famous experiment in 1796, he published his
work in 1798, in which he coined the term “vaccine” from the Latin word vacca, or “cow” [6].
One of the problems that a data miner is faced with while mining medical data is that
unlike other domains, the medical discipline is in itself diverse and complex. Sensible data
mining requires significant domain expertise and as a result, an active collaboration between
the data miner and the domain specialist [24].
Data availability and accuracy is another issue faced by the data miner. Gathering medical
data is a tedious process and any lack of completeness or level of detail may render the data
to be useless. Ethical and legal issues also need to be addressed when mining medical data.
If, for example, the following rule was discovered:
ZipCode(12345), Age(18− 25), Gender(Male)⇒ Hepatitis B Status(Y es) γ(20%)
Then such a rule may not only be disturbing but could also be considered offensive should
the Zip Code(12345) refer to an indigenous community [10, 24].
Researchers at the Pediatric Brain Tumor Research Program at Children’s Memorial Hos-
pital in Chicago used data mining when they performed gene expression analysis for pediatric
cancers. They were able to isolate pediatric leukemia CD markers (antibodies that bind to
proteins on the subraces of white blood cells and leukemic cells) and hope to use that knowl-
edge to improve existing methods of diagnosis and treatment of the disease. [14]
15
Our goal was to use data mining techniques, specifically the Apriori algorithm, to discover
new association rules from current patient data and encode newly-discovered rules into the
MEANS implication subsystem [1, 2, 11].
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CHAPTER 3
IMPROVEMENTS THROUGH AUTOMATED DATA ANALYSIS
3.1 Data Collection
3.1.1 Implementation in a Clinical Setting
Before the system could be used by physicians, it had to be properly and securely set up
for use. Since the system is a web-based tool, no installation was needed on the physicians’
computers and only an Internet Explorer shortcut had to be placed on the desktop. Necessary
precautions were taken to comply with the Health Insurance Portability and Accountability
Act (HIPAA) privacy rule of 1996. HIPAA is the first Federal protection rule for the privacy
of personal health information [22].
The MEANS system was launched on February 7, 2006 at Moffitt Cancer Center’s Gas-
trointestinal (GI) clinic. The decision was made to introduce the system to nurses and physi-
cians at the same time. Because the system was part of the study and had a separate study
protocol number, all of the patients that were screened by the system had to sign a five-page
HIPAA research authorization. Only after the HIPAA authorization was signed by the patient
or guardian, could the patient be screened. Since the goal of the system was to screen patients
that come to the clinic for the first time, only those who were seeing a gastroenterologist for
the first time were considered as potential candidates for screening. As mentioned earlier,
only after a patient signed the HIPAA authorization was his or her information entered into
the system.
3.1.2 GI Clinical Trials
During April of 2006 the number of all active clinical trials at the Moffitt Cancer Center
was 140 [15]. Since our study was aimed only at Phase II clinical trials, only active and open
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for enrollment Phase II clinical trials were entered into MEANS. At the time of this study,
Moffitt Cancer Center had 36 active Phase II clinical trials, five of which were conducted in
the GI Clinic. The five active Phase II GI clinical trials, listed in Table 3.1, were encoded into
MEANS.
Table 3.1 Active Phase II GI Clinical Trials
Protocol # Trial Description
1 13424
A Phase II Study of Capecitabine in Combination with
Irinotecan and Oxaliplatin (Eloxatin) in Adult Patients
with Advanced Colorectal Cancer
2 13426
A Phase II Study of Cisplatin and Irinotecan Induction
Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients
with Surgically Unresectable and/or Metastatic Esophageal
or Gastric Carcinomas
3 13449
Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
(For advanced or metastatic non-resectable colon cancer)
4 13946
Pharmacogenomic Study of Neoadjuvant Pre-irradiation
Docetaxel and Cisplatin, followed by Neoadjuvant Concomitant
Docetaxel, Cisplatin and Irradiation, followed by
Surgery (DC-DCR-S) in Adult Patients with Operable
Adenocarcinomas of the Esophagus or Gastroesophageal Junction
5 14607
Randomized phase II study of AG-013736 and Gemcitabine in
Chemo-Naive Pancreatic Cancer Patients
3.1.3 Patient Selection
We collected our data at the GI Clinic of theMoffitt Cancer Center . There are three types
of patients in the clinic: New Patient (NP), New Established Patient (NEP) and Established
Patient (EP). Table 3.2 provides explanations of each patient type. It was our goal to screen
every new patient for eligibility for clinical trials in the GI Clinic; hence, our study focused
only on NP and NEP patients.
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Table 3.2 Patient Type in the Clinic
Type Explanation
New Patient (NP)
Never seen the doctor at the clinic
-First Time Visit
New Established Patient (NEP)
Previously been seen by another
doctor at the clinic
Established Patient (EP)
Previously seen this doctor.
-Repeat visit
3.2 Experiments and Results
This section describes the data mining experiments that we conducted and our findings.
3.2.1 About Patient Data
We collected data on current NP and NEP patients at the GI Clinic of Moffitt Cancer
Center . Since patients were going through treatment, not all patient data – such as test
results – were available during the initial screening.
MEANS tracks each patient via a patient profile. Each patient profile contains the list of
protocols for which he or she was screened together with the list of all answered questions.
A patient can be determined ineligible anytime during the screening process. If a patient
was ruled out after completion of the initial questions page, then the number of answered
questions could be 10 (if all of the questions on the initial page were answered); however, if
a patient was ruled out by the last question in the eligibility criteria of each protocol, the
number of answered questions in a patient’s profile could be 90. Based on that, each patient
profile could contain a different number of questions.
Since we were working on a new system, there is no archival data available for analysis.
We decided to start the mining patient data after collecting the data for approximately three
weeks. Therefore, our data was divided into two sets: Subset (Data Set One), which consisted
of 161 GI patients whose data was collected from February 7th to March 1st and Superset
(Data Set Two), which is the extension of the Subset and included GI patient data from
February 7th to April 21st.
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I must clarify the fact that the data that was used in all of the experiments did not contain
any potentially identifiable patient information. An anonymous patient profile was assigned
a number and that number was used during the experiments.
3.2.1.1 Data Extraction
Before patient data was mined, some preprocessing was done. We used WEKA, a data
mining software toolkit from the University of New Zealand, to discover new association
rules [29]. To convert the data from the MEANS format to a format usable by WEKA, a
suite of tools was developed by the author of this thesis. These tools permitted necessary pre-
and post-processing, such as data extraction, analysis, cleaning, formatting and rule recovery.
The suite was written in C and C++. The tools are included on the CD that accompanies
this thesis.
The Apriori algorithm does not accept continuous values so the questions that had contin-
uous values as an answer needed to be excluded from the list of questions. The encoding of the
GI protocols into MEANS produced a total of 225 questions. Of the 225 questions, 33 of them
required continuous values. Default questions answered during the streamlining process, such
as Signed Informed Consent, would not contribute to the discovery of new association rules
since all patients had the same answer; therefore, default questions needed to be excluded
from patient profiles.
Using pre-processing tools, patient data was analyzed. Continuous valued questions – as
well as default questions – were removed from patient profiles. The maximum number of
questions that a patient profile could have was 192. Each patient’s information then could be
viewed as a vector with a size between 0 (zero) and 192.
Patient data was retrieved from MEANS and stored in a single .arff file so it could be
read by the data mining software package. The details about the .arff format are covered in
WEKA’s documentation [29].
Because we were looking for implications that always hold, we used the confidence c of 1
(100%) for all of our experiments and varied the minimum support s from run to run. The
data mining software we used starts each run at s = 100% and decreases s by 5% until a given
minimum support is reached.
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3.2.2 Mining Medical Implications
As seen in Figure 2.1, implications are part of the knowledge base. Implications allow us to
make inferences based on existing information, therefore decreasing the number of questions
needed to be asked for eligibility determination.
Example: Based on the sample questions in Table 3.3, we can construct several implica-
tions. If Q1 is answered Male, and since it is known that only females can be pregnant, then
the following implication can be made: If Q1=Male IMPLIES Q2=No. This implication is
always true (confidence = 100%). An implication that has a confidence < 100% – for example,
Q2=No IMPLIES Q1=Male – is false in some cases – a female that is not pregnant – can not
be considered a valid implication.
Table 3.3 Implication Example
Q1 = Patient’s Sex (Male/Female)?
Q2 = Pregnant (Yes/No)?
Q3 = Patient’s Age?
Valid Implications (Confidence = 100%):
X If Q1=Male IMPLIES Q2=No
X If Q1=Female and Age ≥ 70 IMPLIES Q2=No
Invalid Implication (Confidence < 100%):
× If Q2=No IMPLIES Q1=Male
Our goal was to use data mining techniques, specifically the Apriori algorithm, for the
generation of association rules. The association rules were mined using WEKA [2, 29]. The
encoding of the MEANS data (pre-processing), the decoding of the rules, and discovery of
the rules of interest (post-processing) was performed using post-processing tools that where
written by the author.
3.2.2.1 Subset (Data Set One)
During the pre-processing phase we found that of the 175 patients, 14 patients contained
only default answers in their profile. These patients would not provide any useful information
and so were not considered in this experiment. We also found that there were 33 questions
that required continuous values for an answer. Since the Apriori algorithm does not deal with
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continuous values, these 33 continuous valued questions were excluded from the remaining
patient profiles. The result of the pre-processing was a single file that could be viewed as 161
patient vectors with 192 possible dimensions.
For this experiment, 161 records – each with a possible 192 dimensions – were mined.
Since we were looking for implications that always hold, a confidence of 100% (c = 1) was
used. We started with minimum support (s) of 95% and decreased it by 5% until s = 5%.
The first run that produced any result was at a minimum support of 70% (Figure 3.1).
With a minimum support of 70%, only 4 rules were generated at c = 100%. After the rules
were decoded, the analysis of the rules – shown in Figure 3.1 – sparked some interest. It was
found that rules two (2), three (3) and four(4) were permutations of rule one (1):
000 y1y=No ⇒ 009 y1y=No
Rule one (1) had a coverage of 128 which is greater then the rest of the rules generated
during this run.
Figure 3.1 Apriori Run (s=70%)
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The decoded version of rule one (1) is shown in Figure 3.2. This new association rule was
reviewed by a physician and deemed medically valid. I should note that [000 y1y] belongs to
protocol #13426 and question [009 y1y] belongs to protocol #13946. We found an association
rule between two protocols. This was a promising beginning; we found a simple, medically-
valid implication. This implication was added to the implication module of MEANS.
1. 000 y1y=No 128 ⇒ 009 y1y=No 128 conf:(1)
Question: [000 y1y]
[Path diagnosis of esophageal SCC or ACA?] = [No]
Occurred [128] Times:
IMPLIES ⇒
Question: [009 y1y]
[Tissue confirmed esophageal adenocarcinoma or adenocarcinoma
of the gastroesophageal junction] = [No]
Occurred [128] Times:
With conf:(1)
Figure 3.2 Decoded Implication
We continued running experiments by decreasing the minimum support s. As mentioned
earlier, each run starts with s = 100% and decreases s by 5% until a given minimum support
is reached; therefore, the rules that were recovered at s = 70% also showed up in during
subsequent runs when minimum support was < 70%. Since 4 rules may not have encompassed
everything of interest, I continued to decreased minimum support. When s was decreased to
60%, 14 new rules were generated. Table 3.4 contains the association rule summary for the
subset.
We were also curious if there were any implications within a set of questions for each
protocol. During data collection, some of the clinicians chose to screen some patients only for
a subset of our trials; therefore, not all patients were screened for all five trials. Table 3.5 shows
the results of the per protocol mining experiment at s=10% on the subset. Only protocols
13424 and 13946 produced any rules of interest. However, when these rules were examined for
medical validity, none of the 13 rules for 13424 and 15 rules for 13946 were medically valid.
Since a very large number of association rules could be found, we stopped the analysis of
the rules at s = 5%. At minimum support of 5% the last rule had a coverage of 8.
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Table 3.4 Subset: Patient Data
Min Support (s) % Min Coverage (#) # Rules # New Rules
70 114 4 4
60 97 18 14
50 83 30 12
40 78 32 2
30 48 103 71
20 32 362 259
10 16 2,537 2,175
5 8 49,564 47,027
Table 3.5 Subset: Rule Statistics Per Protocol (s = 10%)
13424 13426 13449 13946 14607
Total Patients 158 157 158 154 157
Total Answers 686 590 665 444 502
Rules Recovered 20 0 0 39 0
Rules Of Interest 13 0 0 15 0
Medically Valid Rules 0 0 0 0 0
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In the end we discovered 2 true rules and 5 conditional rules. The final list of medically
valid rules from the subset is listed in Figure 3.3 (Subset: All Medically Valid Implications).
An explanation of this figure will be discussed in Section 3.2.2.3.
Subset: All Medically Valid Implications
· · · 2 True Rules · · ·
#1: [Path diagnosis of esophageal SCC or ACA?] = [No]
IMPLIES ⇒
[Tissue confirmed esophageal adenocarcinoma or adenocarcinoma
of the gastroesophageal junction] = [No]
#5471: [Metastatic colon or rectal cancer (tissue proven)
and not suitable for surgery?] = [Yes]
IMPLIES ⇒
[Histologically confirmed metastatic colorectal cancer?] = [Yes]
· · · 5 Conditional Rules · · ·
#3393: [Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (if same tissue sample) ⇒
[Metastatic colon or rectal cancer (tissue proven)
and not suitable for surgery?] = [No]
#3394: [Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (if same tissue sample) ⇒
[Tissue confirmed esophageal adenocarcinoma or adenocarcinoma
of the gastroesophageal junction] = [No]
#3395: [Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (if same tissue sample) ⇒
[Histologically confirmed metastatic colorectal cancer?] = [No]
#3397: [Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (if same tissue sample) ⇒
[Path diagnosis of esophageal SCC or ACA?] = [No]
#206(modified) Rule has 1 antecedent and 1 consequent:
[001 y1y] [Measurable disease (RECIST)?] = [No]
IMPLIES (if same tissue sample) ⇒
[000 y138y] [Tissue proven pancreas adenocarcinoma?] = [No]
TOTAL: 7 implications
Figure 3.3 Subset: All Medically Valid Implications
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3.2.2.2 Superset (Data Set Two)
Our superset was the extension of the subset. As more and more patients were screened,
the data available for mining increased. Our superset had to go through some pre-processing
before the mining could begin.
We started with 393 patient records; however, after pre-processing, we discovered that
26 of the patient records contained only default questions and/or a combination of default
questions and continuous values. We ended up with only 367 patient records, which meant
that our superset contained 206 more patient records than the subset. Since the pool of the
questions had not changed, each patient record could contain up to 192 possible dimensions.
The superset contained a total of 5055 answers from 367 patients.
Like before, we started data mining with a minimum support of 95% and decreased it by
5% until it reached 5%, keeping the confidence at 100%. In comparison to the subset, we did
not get any rules at s=70%. The first result for the superset was produced at s=30%. As
shown in Table 3.6, at s=30% we found 27 rules. The minimum coverage for the last rule
at s=30% was 111 instances. We continued to decrease the minimum support until 5%. We
stopped at s=5% with the discovery of 7079 rules.
Table 3.6 Superset: Patient Data
Min Support (s) % Min Coverage (#) # Rules # New Rules
30 111 27 27
20 73 71 44
10 37 343 272
5 18 7,079 6,736
We also took a look at the data on a per protocol basis. The result of this experiment on
the superset at s=5% is shown in Table 3.7. As mentioned earlier, clinicians have a choice of
selecting any combination of protocols for which to screen a patient. As a result, the number
of patients screened differed between protocols. However, protocols 13424, 13449 and 14607
had the same number of patients.
Even though we a discovered significant number of rules, they needed to be analyzed before
anything could be said about them. We still needed to validate them to make sure they made
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Table 3.7 Superset: Rule Statistics Per Protocol (s = 5%)
13424 13426 13449 13946 14607
Total Patients 362 361 362 355 362
Total Answers 1658 1426 1588 907 1303
Rules Recovered 2 0 0 2 0
Rules Of Interest 1 0 0 1 0
Medically Valid Rules 0 0 0 0 0
sense and to confirm their medical validity with a physician. By comparing the subset rules
(Table 3.5) and the superset rules (Table 3.7), we can see that the subset had a greater number
of rules that were discovered; however, the number of medically valid rules for both were the
same – zero.
3.2.2.3 Rules of Interest (Subset)
Before we could claim that we found new implications, we needed to analyze the rules for
permutations and medical validity. I will first discuss our findings on the subset data. Later, I
will demonstrate how these discoveries helped us come up with a filtering heuristic to narrow
our search during the superset analysis. The rule numbers referred to from now on refer to
the discovery sequence of the rules and not the rule sequence of valid rules.
The run at s = 20% on the subset produced a total of 362 new association rules. The
rule set was analyzed in terms of the number of antecedents and consequents. The matrix in
Table 3.8 shows the breakdown. The rows represent the number of antecedents and columns
represent the number of consequents in a rule. We can see that our rule set contains rules
with up to 7 antecedents and 3 consequents.
The rules from the subset run at s = 20% were analyzed for medical validity. We found
that of 362 rules, 201 rules were medically invalid; however, 161 rules were medially valid
and were of interest. Further analysis of the rules revealed that of 161 rules of interest, 158
were permutations of valid rules. Only 3 rules (1, 206, and 213) out of 362 were found to be
medically valid. The rule summary table for the subset rule analysis at s = 20% is shown in
Table 3.9.
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Table 3.8 Subset: Antecedent-Consequent Matrix (s = 20%)
Ant/Cons Matrix
1 2 3
1 1 0 0
2 26 9 2
3 78 25 4
4 102 20 0
5 66 5 0
6 20 1 0
7 3 0 0
Table 3.9 Subset: Rule Analysis (s = 20%)
Rule Type #
Invalid Rules 201
Permutations 158
Valid Rules 3
A closer look at the 3 valid rules (Figure 3.4) revealed that rule one (1), which was actually
discovered at s=70%, was the only simple rule. Rules two (2) and three (3) both had two
antecedents, one of which they shared.
The results of our experiments on the subset data indicated to us that we should have con-
centrated on the rules that contained a maximum of two antecedents and only one consequent.
For example:
A ⇒ C
A ∧ B ⇒ C
As mentioned earlier, rules #206 and #213 had the same first antecedent (Figure 3.4).
We first examined rule #206, which was the second rule on our list (Figure 3.4). After
taking a closer look at the subset data, we found that of 160 patients, 2 patients did not
have the answers for two questions, [000 y64y] and [000 y138y]. We removed these two pa-
tients from our data and ran the experiment again. We found that aside from the existing
rule #1 (Figure 3.4), there were two additional simple rules, 1 antecedent and 1 consequent
(Figure 3.5). So with the additional analysis of our data, we were able to come up with the
simple rule.
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Subset: Valid Implications (s = 20%)
1) Rule #1 has 1 antecedent and 1 consequent:
[000 y1y] [Path diagnosis of esophageal SCC or ACA?] = [No]
IMPLIES ⇒
[009 y1y] [Tissue confirmed esophageal adenocarcinoma or adenocarcinoma
of the gastroesophageal junction] = [No]
2) Rule #206 has 2 antecedents and 1 consequent:
[001 y1y] [Measurable disease (RECIST)?] = [No]
– AND –
[000 y64y] [Any histopathologically proven diagnosis of malignant GIST that is
not amenable to standard therapy with curative intent?] = [No]
IMPLIES ⇒
[000 y138y] [Tissue proven pancreas adenocarcinoma?] = [No]
3) Rule #213 has 2 antecedents and 1 consequent:
[001 y1y] [Measurable disease (RECIST)?] = [No]
– AND –
[000 y125y] [Metastatic colon or rectal cancer (tissue proven) not suitable
for surgery?] = [No]
IMPLIES ⇒
[000 y138y] [Tissue proven pancreas adenocarcinoma?] = [No]
Figure 3.4 Subset: Valid Implications (s = 20%)
Subset: Rule 206 (Closer Look)
1) Rule has 1 antecedent and 1 consequent:
[001 y1y] [Measurable disease (RECIST)?] = [No]
IMPLIES ⇒
[000 y138y] [Tissue proven pancreas adenocarcinoma?] = [No]
2) Rule has 1 antecedent and 1 consequent:
[001 y1y] [Measurable disease (RECIST)?] = [No]
IMPLIES ⇒
[000 y64y] [Any histopathologically proven diagnosis of malignant GIST that
is not amenable to standard therapy with curative intent?] = [No]
Figure 3.5 Subset: Rule 206 (Closer Look)
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After the simple rules (Figure 3.5) were reviewed a physician, it was discovered that rule
#2 was not valid; however, rule #1 was validated, but only under certain assumptions. I will
discuss medical validation in detail in Section 3.2.2.5.
When the minimum the support was dropped to 5%, mining of the subset produced 49,564
rules (Table 3.4). After analysis of the rules, we discovered that 100 of them were simple rules.
Table 3.10 shows us that this set of rules contained only 100 simple rules. We will restrict our
analysis to these rules.
Table 3.10 Subset: Antecedent-Consequent Matrix (s = 5%)
Antecedents(row)/Consequents (col) Matrix
1 2 3 4 5 6 7 8
1 100 175 241 245 177 85 24 3
2 997 1,566 1,719 1,307 662 200 27 0
3 3,205 4,274 3,669 2,035 672 100 0 0
4 4,858 5,308 3,429 1,274 213 0 0 0
5 3,938 3,364 1,506 2,94 0 0 0 0
6 1,825 1,108 269 0 0 0 0 0
7 477 160 0 0 0 0 0 0
8 58 0 0 0 0 0 0 0
When we look at the subset data at a minimum support of 5% we find that of 100 simple
rules, only 6 were valid. Rule #1, was previously seen at s=20%. Rules 5471, 3393, 3394,
3395, and 3397 were newly discovered. I should mention that rule 5471 is a true rule, which
means it refers to the same tissue type (colorectal).
3.2.2.4 Rules of Interest (Superset)
Let’s take a look at the rules discovered in our superset. All rule numbers from now on
refer to the superset rules unless otherwise noted. Table 3.11 is a snapshot of the discovered
rules from the superset. Again, our rules of interest only include rules with a maximum of
two antecedents and exactly one consequent. In the table we can see that there are 13 one-
antecedent, one-consequent rules and 241 two-antecedents, one-consequent rules, a total of
254 rules of interest.
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Table 3.11 Superset: Antecedent-Consequent Matrix (s = 5%)
1 2 3 4 5 6
1 13 7 4 1 0 0
2 2,41 128 82 40 13 2
3 903 475 226 82 14 0
4 1,303 716 303 65 1 0
5 1,034 509 134 5 0 0
6 461 159 12 0 0 0
7 116 17 0 0 0 0
8 13 0 0 0 0 0
Antecedents(rows)/Consequents (cols)
After examining the 254 rules of interest of in our superset, we found that 73 rules had
some potential; however, closer examination was needed. Since our 254-rule pool consisted of
rules with a maximum of two antecedents and only one consequent, it is interesting to note
that only 4 of the 73 rules had one antecedent and one consequent pair. The rest had two
antecedents. Out of the 4 rules with one antecedent, only one rule (rule #998) was the true
rule (not dependent on any assumptions). The other three (#1355, #1356, #1357) could only
be validated under the assumption that the antecedent and consequent of the rule referred to
the same tissue sample.
Now let’s take a look at the rules with two antecedents and once consequent. We can see
that there are five (5) rules that looked promising (rules #1, #343, #1347, #7036, #7076). It
was interesting to discover that the rule #1 from Figure 3.2, which was found during analysis
of the subset, acquired an additional antecedent (Sex = Female). A similar case occurred
with rules #343 and #7036. Superset rules #343 and #7036 were the same as the subset
rule #5471 except that #343 acquired an additional antecedent (Take Medications By Mouth
= YES) while #7036 acquired a different antecedent (Uncontrolled Medical Conditions =
NO). I will discuss these findings in greater detail during the Medical Validation discussion
(section 3.2.2.5).
The final count of rules that was discovered from the superset was 9. Table 3.12 lists
the newly discovered rules from the superset together with the number of antecedents and
consequents per rule and medical comments. I will expand on the medical comments in the
next section.
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3.2.2.5 Medical Validation (Subset)
Because we were mining medical data and not supermarket data, we were presented with an
additional challenge during the rule-interpretation phase–that of rule validation. The domain
knowledge needed for medical validation of the rules was provided by the physicians at the
Moffitt Cancer Center , Dr. Chris Garrett and Dr. Amit Pathak. All of our findings were
checked by these physicians for medical validity. Rule interpretation from a medical standpoint
can, at times, be subjective. I spent a lot of time with Dr. Amit Pathak discussing how the
discovered rules should be interpreted for our purpose.
Here are some of the issues we were faced with. Figure 3.3 lists all of the 7 valid implications
that were discovered from our subset data. We can see that only 2 (#1 and # 5471) of the
7 implications were specific enough because the questions mention the same region of the
body in the antecedent and consequent. As seen in Figure 3.3 in implication #5471, both the
antecedent and consequent refer to colorectal type cancer; therefore, this rule is tissue-specific
and did not require any additional assumptions.
In order for the other 5 implications to be valid, we had to make the assumption that both
the antecedent and consequent refer to the same tissue sample. Let’s take a closer look at the
subset rule #3395 from Figure 3.3:
[Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (With assumption that the same tissue was examined) ⇒
[Histologically confirmed metastatic colorectal cancer?] = [No]
Explanation: The logic behind this is that, if a physician is looking at the pancreatic tissue
and it is proven that this tissue is cancerous, then it is also known that this tissue is not from
the colorectal region and therefore will not contain a colorectal cancer.
Since the rest of the questions from the subset were somewhat general, the medical decision
about them was based on the assumption that the antecedent and consequent refers to the
same tissue sample.
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3.2.2.6 Medical Validation (Superset)
Now let’s look at the superset data (all of the subsequent rule numbers will refer to superset
rule numbers). After analyzing the superset data, we found 9 rules of interest (Table 3.12).
We see that of the 9 rules there was only 1 true rule (#998) since both the antecedent and
consequent of the rule referred to the cardiac region. Rules #1347, #1355, #1356, #1357,
and #7076 are tissue dependent rules. Two of these 5 rules contained 2 antecedents; however,
upon medical evaluation it was determined that one of the antecedents was not necessary in
order for the implication to remain valid (1 ANT not needed). I will give an example of such
a case later in this section. Superset rule #1 was a variation of simple rule #1 discovered in
our subset. Rules #343 and #7036 had two antecedents and were variations of the subset’s
simple rule #5471.
Table 3.12 Superset: Discovered Rules
Superset Discovered Rules
Rule # Type #ANT #CON Medical Comments
1 Variation of Subset #1 2 1 1 ANT not needed
343 Variation of Subset #5471 2 1 1 ANT not needed
998 True 1 1 Superset
1347 Tissue Dependent 2 1
Specific to General
1 ANT not Needed
1355 Tissue Dependent 1 1 Must Be Same Tissue
1356 Tissue Dependent 1 1 Must Be Same Tissue
1357 Tissue Dependent 1 1 Must Be Same Tissue
7036 Variation of Subset #5471 2 1 1 ANT not needed
7076 Tissue Dependent 2 1 1 ANT not needed
If rule A ∧ B ⇒ C was discovered during data mining, it would be incorrect to say that
it could be broken down into two rules (A ⇒ C and B ⇒ C) and that these new rules would
have the same confidence level as A ∧ B ⇒ C. If the data could support it, then these two
simple rules would have shown up prior to the combination rule A ∧ B ⇒ C but only if they
had an equal confidence level to A ∧ B ⇒ C (we require 1.0). However, in our case, we were
able to use medical knowledge to simplify such rules. The example in Table 3.13 demonstrates
our reasoning behind doing simplification based on medical knowledge. If a rule A ∧ B ⇒ C
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was discovered, and after medical evaluation, it was determined that the first antecedent (A)
of the rule was not needed, then based on medical knowledge the rule could be reduced to B
⇒ C and still maintain the confidence level of 100%. I must emphasize again that such a rule
reduction would not be correct if based only on data.
Table 3.13 Example: Rule Simplification Based on Medical Knowledge
RULE: A ∧ B ⇒ C
A) [Age Over 18]† = [Yes]
B) [Sex] = [Male]
IMPLIES ⇒
C) [Pregnant] = [No]
MEDICAL KNOWLEDGE: Only female can be pregnant.
REASONING: Since male can not be pregnant, question A [Age Over 18] is
not necessary for the above rule to be valid.
SIMPLIFIED RULE: B ⇒ C
B) [Sex] = [Male]
IMPLIES ⇒
C) [Pregnant] = [No]
† - Antecedent Not Necessary
Let’s take a closer at look why the simple rule #1 from Figure 3.3 that was discovered
during the mining of the subset ended up with 2 antecedents in our superset. Since we used
100% confidence, we only got rules that were correct 100% of the time based on our data. So
when the Apriori algorithm was run on the superset with the confidence of 100%, we got our
subset rule #1 with an additional antecedent (Sex=Female). However, when the confidence
level was dropped to 90%, we got a one antecedent, one consequent superset rule that matched
the subset rule #1 exactly. A closer look at the patient data revealed that one of the patients
contain the following answers:
A) [Sex] = [MALE]
B) [Path diagnosis of esophageal SCC or ACA?] = [No]
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C) [Tissue confirmed esophageal adenocarcinoma or adenocarcinoma of the
gastroesophageal junction] = [Yes]
Medical examination revealed that if B [Path diagnosis of esophageal SCC or ACA] is
NO, then C [Tissue confirmed esophageal adenocarcinoma or adenocarcinoma of the gastroe-
sophageal junction] must also be NO. Since the answer for B was Y es, the antecedent A
[Sex=Female] surfaced for the rule. I’ve already stated that to be medically valid C must be
NO, and since it was Y es this case revealed an error in the data entry.
We see that by using data mining we could find rules of interest. Because we were dealing
with the medical field, we needed to recruit the services of a physician in order to validate
our rules of interest. By relying on his or her medical knowledge, the physician is able to
trim down a rule by dropping an antecedent if the presence of the antecedent is not medically
necessary for the rule to be valid (Table 3.13). Figure 3.6 contains the final result of our data
mining from the superset.
Even though we discovered 7 rules in the subset and 9 rules in the superset (two of which
were previously discovered in the subset) we can only use the rules that do not rely on any
assumptions. We call such rules true rules. By listing only the true rules, which are marked
with () and shown in Figure 3.6, we end up with our final list of five (5) implications. Our
final list of implications is seen in Figure 3.7. These implication have been entered into the
implication module of MEANS.
3.2.3 Probability-Based Reordering
MEANS uses analytical and probabilistic agents to reorder the list of unanswered questions
(questions to ask). The Analytic heuristic is based on the cost of medical tests together with
the structure of the acceptance and rejection expressions. The probability-based reordering
is done with the help of the probabilistic agent. The probabilistic agent uses data that was
accumulated over time to calculate the probability for a question. In this section, I will discuss
the probability-based heuristic in detail.
Bayesian Networks seem to be preferred for probabilistic expert systems; however, there
are some drawbacks to using them. They can be very complex and computationally expensive.
35
Superset: All Medically Valid Implications
#1: ‡ [Sex]† = [Female] AND [Path diagnosis of esophageal SCC or ACA?] = [No]
IMPLIES ⇒ [Tissue confirmed esophageal adenocarcinoma or
adenocarcinoma of the gastroesophageal junction] = [No]
#998: [Prior cardiac condition in the last 6 months?] = [No]
IMPLIES ⇒ [Unstable angina?] = [No]
#1355: [Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (if same tissue sample) ⇒ [Tissue confirmed esophageal
adenocarcinoma or adenocarcinoma of the gastroesophageal junction] = [No]
#1356: [Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (if same tissue sample) ⇒
[Histologically confirmed metastatic colorectal cancer?] = [No]
#1357: [Tissue proven pancreas adenocarcinoma?] = [Yes]
IMPLIES (if same tissue sample) ⇒
[Path diagnosis of esophageal SCC or ACA?] = [No]
#343: [Take medications by mouth?]† = [Yes] AND
[Histologically confirmed metastatic colorectal cancer?] = [No]
IMPLIES (if same tissue sample) ⇒ [Metastatic colon or rectal cancer
(tissue proven) AND not suitable for surgery?] = [No]
#1347: [Histologically confirmed metastatic colorectal cancer?]† = [No]
AND [Tissue confirmed esophageal adenocarcinoma or adenocarcinoma
of the gastroesophageal junction] = [Yes]
IMPLIES ⇒ [Path diagnosis of esophageal SCC or ACA?] = [Yes]
#7036: ‡ [Metastatic colon or rectal cancer (tissue proven) and not suitable
for surgery?] = [Yes] AND [Uncontrolled medical conditions?]† = [No]
IMPLIES ⇒ [Histologically confirmed metastatic colorectal cancer?] = [Yes]
#7076: [Histologically confirmed metastatic colorectal cancer?] = [Yes] AND
[Prior cardiac condition in the last 6 months?]† = [No]
IMPLIES ⇒ [Measurable disease (RECIST)?] = [Yes]
† Antecedent NOT Necessary ‡ Rule Previously Found in Subset  True rule
TOTAL: 9 implications
Figure 3.6 Superset: All Medically Valid Implications
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Final List of Discovered Association Rules
True Rules:
1
[Path diagnosis of esophageal SCC or ACA?] = [No]
IMPLIES ⇒
[Tissue confirmed esophageal adenocarcinoma or adenocarcinoma
of the gastroesophageal junction] = [No]
Superset Rule #1
Subset Rule #1
2
[Metastatic colon or rectal cancer (tissue proven)
and not suitable for surgery?] = [Yes]
IMPLIES ⇒
[Histologically confirmed metastatic colorectal cancer?] = [Yes]
Superset Rule #7036
Subset Rule #5471
3
[Prior cardiac condition in the last 6 months?] = [No]
IMPLIES ⇒
[Unstable angina?] = [No]
Superset Rule #998
4
[Tissue confirmed esophageal adenocarcinoma or adenocarcinoma
of the gastroesophageal junction] = [Yes]
IMPLIES ⇒
[Path diagnosis of esophageal SCC or ACA?] = [Yes]
Superset Rule #1347
5
[Histologically confirmed metastatic colorectal cancer?] = [Yes]
IMPLIES ⇒
[Measurable disease (RECIST)?] = [Yes]
Superset Rule #7076
Figure 3.7 Final Rules
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Introduction of new evidence requires recalculation of corresponding numerical probabilities
and may require modification to an existing network [8, 23]. However, one of the greatest
advantages of Bayesian Networks is that they are able to predict an outcome even with
absence of some information. This ability gives Bayesian Networks an advantage over rule
based systems. Due to this feature, the na¨ıve Bayes approach was adapted for the probabilistic
agent.
Every time a new set of questions and answers is submitted, the answer to each question
is examined and MEANS makes a determination of the patient’s eligibility on a per protocol
basis. If, after the evaluation of all newly-submitted answers the eligibility of a patient can
not be determined, MEANS compiles a list of questions to ask and presents the user with
the top 10 questions from that list. This cycle continues until the eligibility of the patient is
determined for all selected protocols.
We wanted to make the screening process less time-consuming. If a patient is eligible for
a trial, then all of the questions in the acceptance expression need to be answered; however,
only a small set of questions is required for a rejection expression to be TRUE, thus making a
patient ineligible. One way of decreasing the number of questions that needed to be answered
was to try to make a patient ineligible as soon as possible during the screening process.
We needed to present the user with the questions that would most likely to make a patient
ineligible. This was possible with the use of a probability-based heuristic.
By using a probability-based heuristic we could reorder questions such that the questions
with a higher probability-influenced ranking value of determining a patient’s ineligibility for
a protocol would be closer to the top of the list of questions to ask. Since a question with a
higher ranking of making the patient ineligible for a protocol would be asked first, such an
ordering had the potential to reduce the number of questions that a user needed to answer.
3.2.3.1 Probability-Guided Agent
The original version of the probability-guided agent was developed by B. Goswami [12].
We modified the original implementation of data collection and introduced a threshholding
feature during probability calculation.
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Even though it is not entirely true, in terms of our research, we use class conditional
independence (an assumption that all of the questions are independent of each other). We
eliminated known dependencies by using implications; therefore, the dependent (implied)
questions were not in the list of questions to ask. The screening process could be viewed
as a 2-class problem: Eligible and Ineligible. We treated the questions of the protocols as
our attributes and the values of the questions as an eligibility status: either Favorable to be
Eligible or Favorable to be Ruled Out. To use na¨ıve Bayes, we needed know the probabilities
of occurrences of each class type. This was accomplished every time a question was evaluated
by the system.
During the question evaluation phase, we used the following heuristic to keep track of
asked questions and the outcome. Each question had two numbers attached to it together
with a protocol number. The first number kept track of how many times a question ruled out a
patient (made a patient ineligible for a protocol); the second number was the number of times
a question made a patient eligible for a protocol (or did not rule out a patient). Every time
an answer was evaluated for a protocol, one of the numbers would increase. If, the eligibility
of a patient could not be determined even after processing all of the newly submitted answers,
a new list of questions to ask was compiled.
When a patient was screened, the user had a choice of either answering a question, leaving
it blank or deferring the question for later. At this time the system does not capture which
question was answered first on the page or the order of submitted data on a per-page basis;
therefore, we were unable to determine if the question that was answered was the first question
on the list of presented questions. This could be implemented in the future versions of the
system by adding a JavaScript to track the order in which the questions were answered on a
page and capture the data during processing.
We were interested in calculating the likelihood probability that the question would make
a patient ineligible (ruled out) for a protocol. The calculation of the probability was based on
the Bayes’ rule of conditional probability (Equation 3.1). Pr[A] is the probability of the event
A and Pr[A|B] is the probability of the event A conditional to another event B. The evidence
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that consists of a particular combination of attribute values is denoted by E [29]:
Pr[H|E] = Pr[E|H] Pr[H]
Pr[E]
(3.1)
In our case, the probability that a question would rule out a patient from a protocol was
calculated as follows:
Pr[Ineligible|E] = Pr[Ineligible]
Pr[E]
Example: When we collected the statistics for a question Q1, the line that contained the
question was read as Q1 13424 10 80. This could be interpreted as: Question Q1 for protocol
13424, which was asked 90 times, ruled out a patient (made ineligible) 10 times, and did not
rule out a patient (left eligible) 80 times. If we denote A for the number of times a patient
was ruled out and B for the number of times a patient was eligible, then we have:
Pr[rule out|E] =
A
(A+B)
A
(A+B) +
B
(A+B)
which in our case is simplified to:
Pr[rule out|E] = A
(A+B)
(3.2)
By substituting the numbers from our example into Equation 3.2, to calculate the prob-
ability that the question Q1 is likely to rule out a patient from the protocol 13424 would
be:
Pr[rule out|E] = A
(A+B)
=
10
(10 + 80)
= 0.11
It is not uncommon for some protocols to share the same questions, like age and sex.
When a patient is being tested for more than one protocol, a question may appear in the
acceptance criteria in each of the protocols. To take this into consideration, we have chosen
to use a probability-influenced ranking value for our final ordering of the questions. For a
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question that appears in more than one protocol, the probability-influenced ranking value is
calculated by taking an average of individual probabilities and multiplying it by the number
of trials in which the question appears.
If we have question Q1 in three protocols and each individual probability for question Q1
has been already calculated and is:
P (Q113424) = .11 P (Q113426) = .72 P (Q113946) = .51
then the probability-influenced ranking value will be calculated as follows:
Ranking V alue =
(Q113424) + (Q113426) + (Q113946)
3
× 3 =
(.11) + (.72) + (.51)
3
× 3 = 1.34
The resulting probability-influenced ranking value will be between zero and the number of
trials in which a question appears. If a question appears only in one trial, then the probability-
influenced ranking value is equal to the real probability of the question. However, if a question
appears in more than one trial, the probability-influenced ranking value will give an advantage
to such a question because it the has potential of ruling out a patient from multiple trials.
Other ways of calculating a probability-influenced ranking value would be to use a weighted
average of the individual probabilities or only use the maximum probability of a question. If
we use the maximum probability of a question for a trial, that will give the rule-out advantage
to the trial from which the probability was used; however, that may not give the overall
advantage that we are seeking. Such heuristics still need to be explored.
When the probability-based heuristic is used, the list of questions to ask is ordered with
the highest rule-out question ranking at the top.
In order to have a meaningful probability for a question, the number of times a question
should have been asked must be sufficient, that way the questions presented first will have
a greater impact. Let’s say that a question Q2 contains some rare condition and was asked
a total of 9 times, and ruled out a patient only twice. The probability for this question is
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0.22. If we compared the probabilities for Q1 and Q2, the rule-out ranking for Q2 is greater;
therefore, it will be closer to the top of the top of the list of questions to ask. If Q2 did not
rule out any more patients, after some time the rule-out ranking would decrease and Q1 would
move closer to the top of the list; however, this requires additional data entry.
Before using equation 3.2 to calculate the probability on a per-protocol basis, we used a
threshold to evaluate the total number of times a question had been asked. If that number
was above the given threshold, then we calculated the probability for a question. Otherwise,
we assigned the question a probability of zero and did not use the it to reorder.
3.2.3.2 Testing System
To test the probability-guided method we developed a testing system. The testing system,
which was written in C and is on the enclosed CD, was able to screen the patient by submitting
existing answers from patient’s data one question at a time. After an answer was evaluated
and the questions-to-ask list compiled, the testing system attempted to find an answer for
the question from the list of existing answers of a patient. If the answer could not be found,
the system would increase the number of asked questions, and would try to find an answer
for the next question on the list. When an answer for a question was found, the number of
answered questions increased and the answer was submitted into the system for evaluation.
If a patient’s eligibility for a protocol was determined eligible or ineligible, no other questions
from that protocol would appear in the list. If the eligibility for all protocols was determined,
the questions-to-ask list would then be blank and the testing program terminated. The testing
system algorithm is shown in Figure 3.8.
We have created two versions of the testing system: web-based and command prompt-
based. The web-based test system permits screening a patient without logging into the server.
We can test one or two patients and view the results via the browser. However, the command
prompt version is more robust if screening a list of patients.
The command-prompt version takes in one parameter, which is the MEANS ID of the
existing patient. During our experiments, the command-prompt testing system was called via
shell scripts.
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1: for (Each testing patient)
2: {
3: Load default answers
4: Load first page answers
5: Compile questions-to-ask list by using ranking to reorder
6: while (there are questions to ask)
7: {
8: Take top question from questions-to-ask list (ordered by ranking value)
9: Try to find the answer in patient’s profile
10: if (answer not found)
11: {
12: while (answer not found AND there are questions to ask)
13: {
14: Increment number of asked questions
15: Take next question from questions to ask list
16: Try to find the answer in patient’s profile
17: }
18: }
19: Increment number of answered questions
20: if (answer found)
21: {
22: Evaluate patient’s eligibility
23: Compile questions to ask list
24: }
25: }
26: Record Patient’s statistics
27: }
Figure 3.8 Testing System Algorithm
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3.2.3.3 Probability Guided Experiments
For our experiment, we chose 100 ineligible patients. These were the ineligible patients
from the latter part of the data-collection phase. First, each of the 100 test patients were
evaluated by the testing system and a number of asked questions and answered questions
were tracked together with the statistics for each question. Next, the same 100 patients were
evaluated by testing system again, except this time the questions-to-ask list was sorted by
probability-influenced ranking value with the highest rule-out ranking value at the top of the
list.
I should reiterate that the testing system screens a patient one question at a time. A
question is considered presented or asked when a question is at the top of the questions-to-ask
list and the testing system is done searching for the answer in a test patient’s profile.
The results of the analytical reordering experiment are shown in Table 3.14. From the
Questions Answered column we can see that, on average, the system required 7.89 questions
in order to determine a patient’s eligibility. The Less Needed column shows that, compared
to the test profile, the number of questions that were answered during data collection but
were not needed for eligibility determination decreased by an average of 4.46 questions per
patient. The Questions Asked column refers to the number of questions that were presented
(searched-for answers in a test patient) before eligibility was determined. The average number
of questions that was presented was 86.7.
Table 3.14 Analytical Reordering
Questions Questions Questions in Questions in Less
Asked Answered Test Profile Original Profile Needed
Total (
∑
) 8,670 789 1,787 2,233 446
Mean (x¯) 86.7 7.89 17.87 22.33 4.46
Median (Md) 106 8 18 19 2.5
Mode (Mo) 106 8 18 19 1
St. Dev (σ) 52.17 5.19 5.23 8.75 5.73
To compare how the analytical reordering stacked up against the probability-based heuris-
tic, we used the 10-fold cross validation method. We divided our 100 patients into 10 equal
sets of 10 patients per set. We gathered the probability of the 9 sets and then used that prob-
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ability on the 10th set that was left out during the probability gathering. This was repeated
10 times, once per set.
Table 3.15 Probability-Based Reordering (10-Fold Cross Validation)
Questions Questions Questions in Questions in Less
Asked Answered Test Profile Original Profile Needed
Total (
∑
) 1,887 511 1,509 2,233 724
Mean (x¯) 18.87 5.11 15.09 22.33 7.24
Median (Md) 12 4 14 19 5
Mode (Mo) 11 4 14 19 5
St. Dev (σ) 23.13 3.65 3.69 8.75 6.84
The comparison between Table 3.14 and Table 3.15 indicates that using the probability-
based heuristic to reorder the questions-to-ask list decreased the number of questions that were
needed to rule out a patient from clinical trials. By looking at the mean (x¯) we can see that
the average total questions asked for eligibility determination (Questions Asked) decreased
from 86.7 to 18.87. That is a drop of 67.83, which is quite a significant number. The average
number of questions that were answered (Questions Answered) was 5.11, a decrease of 2.78.
I must note that during the initial screening of the patients, clinicians had a choice of
answering any number of the 10 questions on the page in any order before submitting the
answers into the system. Since the system compiled the questions-to-ask list only after eval-
uation of all of the newly-submitted answers, the number of asked questions will differ when
multiple answers were submitted at a time instead of one answer at a time.
As I mentioned before, we were also interested in finding out what happens if we threshold
the number of times a question was asked before calculating probability for the question. For
our next experiment, we used the same 100 ineligible patients and ran the 10-fold cross vali-
dation while varying the threshold value before calculating the probability for each question.
First we ran the 10-fold cross validation with a threshold (T ) of zero. Then we ran the
10-fold cross validation for each threshold value starting at T = 10 until T = 120 while varying
the threshold by 5. As seen in Table 3.16, the number of questions asked when T increased
from 0 to 10 decreased by an average of 8.03. The lowest average of questions asked was 8.60,
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which occurred at T = 55. This can be seen better in the graph in Figure 3.9. We were
interested in the curve with the diamond-shaped data points.
Table 3.16 Probabilistic Thresholding (10-Fold Cross Validation)
Threshold Questions Questions Questions in Questions in Less
Value Asked Answered Test Profile Original Profile Needed
0 17.11 5.02 15.00 22.01 7.01
10 9.08 5.54 15.52 22.01 6.49
15 9.09 5.77 15.75 22.01 6.26
20 9.02 5.74 15.72 22.01 6.29
25 8.87 5.71 15.69 22.01 6.32
30 8.87 5.71 15.69 22.01 6.32
35 8.86 5.71 15.69 22.01 6.32
40 8.77 5.71 15.69 22.01 6.32
45 8.62 5.71 15.69 22.01 6.32
50 8.61 5.71 15.69 22.01 6.32
55 8.60 5.71 15.69 22.01 6.32
60 8.68 5.64 15.62 22.01 6.39
65 8.68 5.64 15.62 22.01 6.39
70 8.68 5.64 15.62 22.01 6.39
75 8.68 5.64 15.62 22.01 6.39
80 8.68 5.64 15.62 22.01 6.39
85 14.24 5.80 15.78 22.01 6.23
90 23.30 6.44 16.42 22.01 5.59
95 23.30 6.44 16.42 22.01 5.59
100 23.28 6.44 16.42 22.01 5.59
105 23.61 6.46 16.44 22.01 5.57
110 23.98 6.60 16.58 22.01 5.43
115 24.36 6.55 16.53 22.01 5.48
120 24.36 6.55 16.53 22.01 5.48
In Figure 3.9 we can see that as T increased from zero, the average number of questions that
needed to be asked in order to rule out a patient decreased. However, when T approached 85,
the curve started going up, with a noticeable jump at T=90. This can be explained by looking
at Table 3.17, which lists for each set the maximum number of times a question was asked
for a protocol. We can see that the average maximum number of times a question was asked
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Figure 3.9 Thresholding (10-Fold Cross Validation)
for a particular protocol was 88. So, when a threshold was set too high, the probability-based
reordering was not in effect and the questions were presented at random.
Table 3.17 Max Number Per Set
Max Number of Times a Question for a Protocol Was Asked
Set 1 Set 2 Set 3 Set 4 Set 5 Set 6 Set 7 Set 8 Set 9 Set 10
87 87 88 88 88 88 88 88 88 90
Average: 88
When sorting by probability-influenced ranking value, it is useful to know when to pick
a starting point in order to insure that the probability calculation for a question will be sig-
nificant enough. Counting the number of patients that have been screened is not sufficient.
Since we were reordering the questions, we needed to use information about each individual
question. We showed that by thresholding the number of times a question was asked before
computing the probability for a question, it decreased the number of questions asked, com-
pared to non-thresholding. By decreasing the number of questions needed to rule out a patient
we decreased the amount of data entry required and possibly decreased the amount of time
spent on the screening process.
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3.2.4 Data Entry Optimization
During the patient data collection phase, we received continuous feedback from physicians
and nurses at the Moffitt Cancer Center GI Clinic. To make MEANS more user-friendly, we
implemented the clinicians’ suggestions.
One of the concerns was the amount of mouse clicks that clinicians needed to make during
the selection of protocols. Based on that, we implemented a protocol bypass option. That
option, which is preselected, automatically selects all of the protocols for which a patient will
be screened. A user has the option of deselecting the automatic selection of protocols if he or
she would like to screen a patient only for a subset of active protocols. If a user decides to
deselect it, then the user may manually pick which protocols to screen a patient for. At least
one of the protocols must be selected in order for the system to proceed.
Another optimization measure, which was implemented based on the suggestions from the
physicians, was the entry of normal lab values. Physicians are only interested if a patient has
abnormal lab values. If the lab values of a patient are all within the normal range, then the
actual lab values are not of particular interest. The same can be said about MEANS’ screening
process. As long as the lab values are within the normal range, a patient will be considered
eligible. Based on that, we implemented a normal checkbox for each question that requires a
lab value. Another related option – All Labs Normal – was also requested by the physicians.
Now, when a physician checks a patient’s labs and is able to determine that all of the lab
values fall within the normal range, a physician can check the All Labs Normal checkbox
and the system will automatically enter all of the predefined lab values into that patient’s
profile. This can be seen in Figure 3.10. Such measures significantly reduces the number of
mouse clicks that a physician must make during the screening process. Implementation of the
above-mentioned changes also had impact on the system flow.
We also found that there was a significant difference between the verbiage used by the
physicians and the legal language in which the protocol inclusion/exclusion criteria was writ-
ten. The legal version can sometimes be much longer, as seen in Table 3.18. To conserve a
physician’s time, only the shorter version of a question was displayed on the screen. The full
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version of the question was viewable by placing the mouse cursor over the question or clicking
on the Full Text link.
Table 3.18 Yes/No Question Length
Full Text
Does the patient have histological or cytological confirmed
esophageal adenocarcinoma or adenocarcinoma of the
gastroesophageal junction? (This refers to tumors at the junction
of the esophagus and the stomach, where > 50% of the
tumor mass is above the diaphragm)
Short Version
Tissue confirmed esophageal adenocarcinoma or
adenocarcinoma of the gastroesophageal junction?
Automatic selection of all encoded clinical trials and the All Labs Normal option were
introduced based on feedback from the physicians. These changes are reflected in Figure 3.10.
3.2.5 Interface Changes
To improve usability of the system, a variety of changes were made to the interface of
the system. The initial questions page is shown in Figure 3.10. We can see that beside each
question there are three choices. If a question is a numeric question, a physician can enter
the actual value, select Normal, and have the system enter a value, or select Defer to delay
answering the question for later.
By clicking on the Full Text link a physician can see the full version of any question. An
example of a full-text pop-up can be seen in Figure 3.11.
To help physicians see when a patient becomes eligible, we added a table that lists the
status of all of the trials during the screening process. When a patient becomes eligible for a
trial, the color of the eligibility slot of the table changes to green. As seen in Figure 3.12, the
first cell of the table is highlighted green, signifying that the patient with ID 105 is eligible
for a trial.
Most of the physicians do not know the clinical trials by their protocol number because
they refer to them by the name of the study. Because of this, we implemented a pop-up that
includes both the protocol number and the full title of the clinical trial. By clicking on the
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Figure 3.10 MEANS Streamlined Initial Questions Page
Figure 3.11 Full Text Popup
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Figure 3.12 Eligibility Color Table
Figure 3.13 Protocol Number and Title
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#Eligible link, a pop-up with the explanation will appear (Firgure 3.13). We received positive
feedback on the changes that we have implemented.
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CHAPTER 4
CONCLUSION
4.1 Implication Discoveries
We used data mining on acquired medical data to flag implications for further physician
evaluation. As a result of our efforts, 14 rules were discovered; however, only 5 of these
rules were true rules and could be entered into MEANS. These 5 implications were added to
MEANS’ implication module.
I should note that one reason we did not find more was because of the way the initial
questions in MEANS were set up. Because we wanted to identify ineligible patients as early
as possible during the screening process, the initial questions page in MEANS contained a set
of questions that were most-likely to make a patient ineligible for a protocol. The initial page
usually contained two key questions from each protocol, and each question was specifically
chosen by a physician to most-likely rule out a patient from a protocol. The majority of the
patients were ruled out after the questions on the first page were answered. The patients that
were not ruled out after the first page were ruled out soon after, unless they were eligible for
a protocol. Since the questions on the first page were not medically related, the number of
rules that could be medically valid decreased tremendously.
We found that by using Apriori we could find many rules. We could isolate our rules of
interest from the rest of the rules by looking at the number of antecedents and consequents.
Our experiments showed that when we were using a confidence level of 100%, it was beneficial
to not only look at one antecedent, one consequent rules but also include two antecedents, one
consequent rules in our rules-of-interest pool. With the help of physicians, we could determine
whether a rule with two antecedents could be simplified by dropping one of the antecedents.
Such a simplification was only possible with the support of medical knowledge.
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I must also note that some of the discovered rules were medically validated based on certain
assumptions. Because some of the questions did not specify the region of the body to which
they were referring, we assumed that the reference was either to the same section of the body
or both the antecedent and consequent of the rule were referring to the same tissue. The data
supported our assumption; however, since the rules could only be validated based upon the
assumption, it was not a good idea to include such rules in our implication subsystem. Due
to this, the rules that required any assumptions, were not included in our final list.
Many decisions in medicine can be subjective; therefore, two physicians may evaluate the
same condition differently. This presents another challenge for medical validation of newly-
discovered rules.
4.2 Probability-Based Reordering
We were interested in minimizing the amount of data entry needed to determine a patient’s
eligibility for a clinical trial (protocol). If a patient is eligible, it is obvious that, all of the
questions must be answered. However, if a patient is ineligible as a result of the screening, it
would be beneficial to ask the question that made the patient ineligible at the beginning of
the screening process.
We were interested in calculating the likelihood probability that a question would make a
patient ineligible (ruled out) for a protocol. We based our calculation of probability on the
Bayes’ rule of conditional probability (Equation 3.1). By calculating probability for each ques-
tion and presenting the user with a question that has a higher rule-out probability-influenced
ranking value, we showed that the average number of questions that were presented (Ques-
tions Asked) by the test system decreased from 86.7 to 18.87 and that the average number of
questions that needed to be answered before eligibility was determined decreased from 7.89
to 5.11.
We also showed that by thresholding the number of times a question was asked, it was
possible to decrease the amount of questions asked during the screening process even more.
By thresholding during the probability calculation, the average number of questions asked
by the system was the lowest when the threshold was between 45 and 80; however, the
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optimal threshold was at 55. At T = 55 the average number of questions asked by the
test system to determine eligibility was 8.60 and the average number of answers required for
eligibility determination was 5.71. Compared to analytical and non-thresholding probability-
based heuristics, this is a significant reduction in the number of questions that were asked
(presented) and answered in order to determine eligibility. At this time the probabilistic
thresholding is only being implemented in test systems.
Since the probability was gathered every time a question was answered, we could set
the threshold value and, as soon as the threshold value was reached, the probability-based
reordering for that question would come into play. If the question was below the threshold
value, probability-based reordering would have no effect on the question ranking and would
be placed in the lower part of the list of questions to ask after all of the questions with a
rule-out ranking value. As time goes by, our system “learns” from submitted answers and
becomes “smarter” over time.
4.3 Optimization
Physicians are very reluctant to use new software, which makes it difficult to introduce
systems to physicians. By using the method participatory design, we used the feedback
that was given to us by the clinicians during the patient screening phase to streamline our
system [17]. The feedback that was received during the fielding of the system was invaluable
to the overall success of MEANS. If the system is not accepted by the users, no matter how
well it functions or how great it is, no one will use it and, as a result, it will fail.
We found that the success of the acceptance of MEANS in a clinical environment depends
heavily on the amount of time that a physician will spend screening a patient. Physicians are
very busy and if the system takes a long time to learn and use, it is less likely that it will
be utilized. We used medical knowledge to select the questions for display on the initial page
because most of the rule-out questions were based on cancer site.
Based on the feedback, we modified the system to decrease the amount of time a physician
spends reading the questions. We also decreased number of mouse clicks required. With one
mouse click a physician can mark all of the lab values as Normal. Since we automated the
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selection of the protocol for physician, no mouse clicks are required to select all protocols for
screening. During the screening process, optimization occurs prior to the probability-based
reordering.
4.4 Future Work
Because of HIPAA regulations, we were unable to interface MEANS with the the electronic
medical records system at H. Lee Moffitt Cancer Center & Research Institute. Therefore,
every time a new patient was screened, all of the patient’s information had to be entered
manually. Because of this, the amount of information available for data mining was very
limited. It would be a great advantage to have some kind of interface where information from
medical records can be imported into MEANS. This would significantly increase the amount
of data available for data mining. It would also decrease the amount of data entry required
for screening patients.
We did not explore this option, but it is possible to automate the entire process of data
extraction from MEANS, running the Apriori algorithm on the data, rule recovery, and rule
filtering based on the number of antecedents in the rule. It would be interesting to see, with
the addition of new data, what rules could be recovered on a weekly basis.
Mining medical data presents a challenge all its own because of the nature of the medical
domain. Recovering rules based on medical data has proved to be a difficult task. Many
questions in the protocols are not specific enough, which in turn presents a gray area when
trying to use medical knowledge to validate a rule. It would be of an advantage to have
clearer wording in the inclusion/exclusion criteria of the protocols. This would help alleviate
confusion if questions are referring to the same tissue.
We only explored the Bayes’ rule of conditional probability with the thresholding option.
The other probabilistic methods should also be explored to see if they may be more effective
in reordering questions for rule-out probability. We used a 10-fold cross validation of 100
patients to conduct our experiments. It would be interesting to see how the system behaves
with a larger number of patients. If the number of patients increases, it may be possible that
a different threshold value would perform better.
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